Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Vittorio Montefusco,[1] Francesca Gay,[2] Stefano Spada,[2] Lorenzo De Paoli,[3] Francesco Di Raimondo,[4] Rossella Ribolla,[5] Caterina Musolino,[6] Francesca Patriarca,[7] Pellegrino Musto,[8] Piero Galieni,[9] Stelvio Ballanti,[10] Chiara Nozzoli,[11] Nicola Cascavilla,[12] Dina Ben-Yehuda,[13] Arnon Nagler,[14] Roman Hajek,[15] Massimo Offidani,[16] Anna Marina Liberati,[17] Pieter Sonneveld,[18] Michele Cavo,[19] Paolo Corradini[20] and Mario Boccadoro[2]

[1]Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; [2]Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; [3]Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont and Maggiore Hospital, Novara, Italy; [4]Division of Hematology, Ospedale Ferrarotto, Azienda Policlinico-Ospedale Vittorio Emanuele, University of Catania, Catania, Italy; [5]Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy; [6]Division of Haematology, University of Messina, Messina, Italy; [7]DAME, Udine University, Udine, Italy; [8]Hematology and Stem Cell Transplantation Unit, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; [9]U.O.C. Ematologia e Trapianto di Cellule Staminali Emopoietiche, Ospedale Mazzoni, Ascoli Piceno, Italy; [10]Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia di Perugia, Perugia, Italy; [11]Cellular therapies and Transfusion Medicine Unit, Careggi University Hospital, Firenze, Italy; [12]Department of Hematology and Stem Cell Transplant Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy; [13]Division of Hematology, Hadassah Ein-Kerem Medical Center, Jerusalem, Israel; [14]Hematology Division, Chaim Sheba Medical Center, Tel-HaShomer, Israel; [15]Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic; [16]Division of Hematology, Ospedali Riuniti, Ancona, Italy; [17]A O S Maria di Terni, S C Oncoematologia, Terni, Italy; [18]Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; [19]Institute of Hematology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, "S. Orsola-Malpighi" Hospital, Bologna, Italy and [20]Hemato-Oncology Department, University of Milan, Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

 doi:10.3324/haematol.2019.219139

Received: February 13, 2019.

Accepted: June 19, 2019.

Pre-published: June 20, 2019.

Correspondence: *VITTORIO MONTEFUSCO* - vittorio.montefusco@istitutotumori.mi.it

Data Supplements

Table of Contents

Endpoints

Overall survival (OS) was calculated from date of study entry to the date of death for any cause or the date the patient was last known to be alive. Progression-free survival (PFS) was calculated from date of study entry to the date of second progression or death for any cause, whichever comes first, or the date the patient was last known to be in remission. Progression-free survival (PFS) was calculated from date of study entry to the date of progression or death for any cause, whichever comes first, or the date the patient was last known to be in remission.

Figure S1: PFS according to extramedullary disease presence



EMD, extramedullary disease.

Figure S2: Subgroup analysis for PFS in the intent-to-treat population for extramedullary versus non-extramedullary



EMD, extramedullary disease.

Figure S3: PFS according to extramedullary disease ≤ or > 5 cm



EMD, extramedullary disease.

Figure S4: OS according to extramedullary disease presence



EMD, extramedullary disease.

Figure S5: Subgroup analysis for OS in the intent-to-treat population for extramedullary versus non-extramedullary



EMD, extramedullary disease.

Figure S6: OS according to extramedullary disease ≤ or > 5 cm



EMD, extramedullary disease.

Figure S7: OS according to extramedullary disease presence and type of therapy



EMD, extramedullary disease; IMiD, immunomodulatory drug; PI, proteasome inhibitor.

Figure S8: PFS2 according to extramedullary disease presence



EMD, extramedullary disease.

FISH testing

Fluorescence in situ hybridization analyses were performed on bone marrow plasma cells purified with anti-CD138–coated magnetic beads as previously described.1 Deletion of chromosome 13 (del13) was analyzed with an locus-specific identifier (LSI) 13 DNA probe; chromosome 17 deletion (del17) was detected with an LSI 17p13.1 probe combined with 17 α-satellite DNA centromere probe. LSI immunoglobulin H (IgH)/fibroblast growth factor receptor 3 dual fusion translocation probe (FGFR3, 4p16) was used for the detection of IgH/FGF3 fusion resulting from t(4;14)(p16;q32); LSI IgH/cyclin D1 (CCND1, 11q13) was used to detect IGH/CCND1 fusion resulting from t(11;14)(q13;q32), and LSI IgH/c-maf (MAF, 16q23) was used for the detection of the IgH/MAF fusion resulting from t(14;16)(q32;q23).

1. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15;64(4):1546-58.